Launch-HTN
98 evidence topics · 20 sources
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Objective stated in the publication
“To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The phase 3 Launch-HTN randomized clinical trial evaluated the efficacy, tolerability, and safety of lorundrostat in participants with uncontrolled hypertension, including those with apparent treatment-resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-11-22” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2024-12-10” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-01-24” (opens the source at this quote in a new tab)
“First Posted 2023-12-01” (opens the source at this quote in a new tab)
“Last Update Posted 2026-05-01” (opens the source at this quote in a new tab)
“No longer looking for participants” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
Enrollment period, sites, and countries reported in the publication
“In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current double-blind, placebo-controlled randomized clinical trial screened participants at 159 sites across 13 countries. The participants were recruited by investigators from primary and secondary care clinics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EU member states, trial start, and end of trial in the EU Clinical Trials Information System record
Trial and recruitment dates by EU member state
| Member state | Status | Decision date | Trial start date | Trial end | Recruitment start | Recruitment end |
|---|---|---|---|---|---|---|
| Spain | “Ended” | “08/04/2024” | “23/04/2024” | “03/01/2025” | “29/05/2024” | “18/10/2024” |
| Germany | “Ended” | “10/04/2024” | “18/04/2024” | “09/01/2025” | “28/05/2024” | “18/10/2024” |
| France | “Ended” | “10/04/2024” | “31/05/2024” | “02/01/2025” | “05/09/2024” | “18/10/2024” |
| Italy | “Ended” | “10/04/2024” | “07/05/2024” | “16/01/2025” | “04/06/2024” | “18/10/2024” |
| Netherlands | “Ended” | “11/04/2024” | “22/05/2024” | “06/01/2025” | “26/08/2024” | “18/10/2024” |
| Poland | “Ended” | “12/04/2024” | “08/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Bulgaria | “Ended” | “15/04/2024” | “17/04/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Romania | “Ended” | “15/04/2024” | “27/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
Study design
Design details in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Parallel Assignment” (opens the source at this quote in a new tab)
“Masking : Double” (opens the source at this quote in a new tab)
“Other Study ID Numbers MLS-101-301” (opens the source at this quote in a new tab)
“Phase Phase 3” (opens the source at this quote in a new tab)
Study periods in the ClinicalTrials.gov detailed description
Trial phase in the EU Clinical Trials Information System record
Trial phases, randomization, and stratification in the publication
“The trial was composed of 3 phases: screening, a 2-week single-blind placebo run-in, and a 12-week randomized, double-blind treatment phase (eFigure 1 in Supplement 1). Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up. Participants continued taking their prescribed antihypertensive medications for the duration of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random permuted block sizes of 4 and 8 were used for randomization, which was stratified by geography (Australia, Canada, Europe, and the US). The randomization sequence was implemented using the Rave RTSM (a randomization and trial supply management system manufactured by Medidata).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding and oversight
“The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6. The treatment assignment was masked to participants, investigators, individuals assessing the outcomes, and individuals analyzing the data until the final database lock.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent, unblinded data and safety monitoring committee assessed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure measurement protocol
“Unattended, automated office BP was assessed at screening, at randomization (baseline), at weeks 2, 4, 6, 8, and 12 during the double-blind treatment phase, and at an optional safety follow-up visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each site was provided with an identical automated oscillometric BP device (MicroLife WatchBP Office AFIB), training, and an instruction manual for collecting BP measurements. All BP was measured with an appropriately sized cuff on the same arm of the participant throughout the trial at approximately the same time, preferably in the morning. After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A standing measurement followed the seated measurements to monitor for orthostatic hypotension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Design described by the company: background medications continued
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age range in the EU Clinical Trials Information System record
Trial population and prohibited medications in the publication
“Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening. The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional inclusion criteria in the supplementary eMethods
Additional exclusion criteria in the supplementary eMethods
Treatment
Arms and interventions in the ClinicalTrials.gov record
Randomization ratio and criteria for escalation to 100 mg at week 6
“Upon confirmation of eligibility for randomization after the placebo run-in phase, participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participants in the lorundrostat group who did not meet all of the prespecified criteria at week 6 continued to receive the 50-mg dose for the remaining 6 weeks of double-blind treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration, dose modification, and adherence reminders
“Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning. Participants were reminded about taking their trial medication using a smartphone application (AiCure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Registered primary and secondary outcome measures in the ClinicalTrials.gov record
Primary outcome and key secondary outcomes in the publication
“The primary efficacy outcome was the change in office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. The key secondary outcomes controlled for multiplicity and included the proportion of participants with an office systolic BP of less than 130 mm Hg at week 6; change in office systolic BP at week 6 in participants taking 2 prescribed antihypertensive medications or taking 3 or more prescribed antihypertensive medications; change in office systolic BP from baseline by continuous body mass index (BMI; calculated as weight in kilograms divided by height in meters squared); change in office systolic BP at week 12; and change in office systolic BP from baseline at week 12 in participants who met prespecified criteria and were escalated from 50 mg to 100 mg of lorundrostat after week 6 (eTable 1 in Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint at week 6 pooled across both lorundrostat groups
Choice of unattended automated office measurement stated by the investigators
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current trial aimed to minimize the variable nature of office BP measurement by (1) obtaining measurements prior to the intake of morning medications, (2) using unattended BP measurements to limit the white-coat effect, and (3) using the mean of repeated BP measurements to reduce intraindividual variability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Automated office blood pressure in the American Heart Association scientific statement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unattended AOBP has been associated with a lower prevalence of white-coat effect compared with office BP measured through auscultation and reduces the possibility of human error in BP measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Difference between unattended and attended automated office measurements
“The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standardized unattended AOBP measurements result in slightly lower readings than attended AOBP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure as the basis of benefit in FDA labeling guidance
Blood pressure in the FDA table of surrogate endpoints
| Disease or use | Patient population | Surrogate endpoint | Type of approval appropriate for |
|---|---|---|---|
| “Hypertension” | “Patients with hypertension” | “Blood pressure” | “Traditional” |
Studies on a background of multiple antihypertensive drugs in FDA draft guidance
Cardiovascular risk reduction per 5 mm Hg lower systolic blood pressure
“In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: office systolic blood pressure below 130 mm Hg
Key secondary endpoint: participants taking 3 or more antihypertensive medications
Key secondary endpoint: obesity and aldosterone dysregulation
“There is increasing awareness that primary aldosteronism and the secondary causes of increased aldosterone production, including obesity and aldosterone breakthrough, contribute significantly to elevated BP and a lack of BP control among patients with hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity hierarchy of the primary and secondary hypotheses
Prespecified adverse events of special interest
“Safety was assessed as the proportion of participants having received at least 1 dose of trial medication experiencing any treatment-emergent adverse events. Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation and power
“The sample size of 1000 participants randomized to 1 of 3 treatment groups in a 1:2:1 ratio had 95% power to detect a difference of 3.7 mm Hg in office systolic BP between lorundrostat (n = 750) and placebo (n = 250) at a 1-sided α level of .025, assuming a common SD of 14 mm Hg for change in office systolic BP. This sample size allowed robust safety monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Actual enrollment in the ClinicalTrials.gov record
Participants randomized and dosed by group
“Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants in the primary analysis
Participants in the chronic kidney disease analysis
Description of analysis sets
Intention-to-treat and safety populations
“Included participants who received at least 1 dose of trial drug according to treatment assignment at randomization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Included participants who received at least 1 dose of trial drug according to the actual treatment they received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant Demographics and Characteristics at Randomization (Baseline) in the Intention-to-Treat Population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary estimand and analysis model
“The primary estimand followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation. The primary outcome was analyzed on 1000 multiple imputed data using analysis of covariance with categorical factors for treatment, geographic region or country (randomization stratification factor), and treatment interaction with geographic region or country and using baseline office systolic BP as a covariate. Canada and the US were merged into 1 geographic stratum because only 3 participants were randomized in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The secondary outcomes were analyzed on multiple imputed data using the analysis methods described in eTable 2 in Supplement 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intercurrent events and handling of missing data
Analysis of the obesity and within-participant secondary hypotheses
Sensitivity analyses of the primary endpoint
Population of the responder analysis
Definition of chronic kidney disease in the subgroup analysis
Results
Participant disposition
Screening, run-in, randomization, and dosing
“Between November 24, 2023, and September 16, 2024, 3161 participants were screened, 1575 entered the placebo-run in phase, and 1083 were randomized to the double-blind treatment phase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most frequent reasons for exclusion
“The most frequent reasons were current use of treatment (or anticipated treatment) with any of the prohibited medications described in the trial protocol within a specified time frame (n = 15); had a condition that would preclude participation in the study (based on the opinion of the investigator) (n = 14); and had current, known, or presumed orthostatic hypotension (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intercurrent events and missing data
Enrollment of lorundrostat-treated participants in the open-label extension
Baseline characteristics
Demographic summary of the randomized population
“Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The randomized groups were comparable for the baseline demographic and clinical characteristics (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics by randomized group
Baseline characteristics of the responder analysis population
Baseline characteristics of participants with chronic kidney disease
Efficacy results
Primary endpoint: change in office systolic blood pressure at week 6
“The least-squares mean change in office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) for the pooled 50 mg of lorundrostat group vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares between-group mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg], P < .001; Table 2 and Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary, secondary, and prespecified exploratory blood pressure outcomes
Observed proportion with office systolic blood pressure below 130 mm Hg at week 6
Key secondary endpoints at week 6
“An office systolic BP of less than 130 mm Hg at week 6 was achieved by 44.1% of participants in the pooled 50 mg of lorundrostat group vs 24.1% of participants in the placebo group (odds ratio, 3.4 [95% CI, 1.5 to 7.8]; P = .003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications. Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoints at week 12 with escalation to 100 mg
“Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2 mm Hg; P = .002) for participants randomized to 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks. Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −10.2 mm Hg (97.5% CI, −14.3 to −6.1 mm Hg; P < .001) for the 92 participants who escalated from 50 mg of lorundrostat to 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup consistency of the primary endpoint
Prespecified exploratory endpoints: diastolic blood pressure at week 6 and systolic blood pressure at week 12
Sensitivity analyses of the primary endpoint
| Analysis | Lorundrostat LS mean (SE) | Placebo LS mean (SE) | LS mean difference (SE) | 95% CI of LS mean difference | P value |
|---|---|---|---|---|---|
| Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270) | “-16.9 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
| Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270) | “-16.5 (1.1)” | “-7.9 (1.9)” | “-8.6 (2.2)” | “-12.2 to -4.4” | “<0.001” |
| Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257) | “-17.0 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
Tipping point sensitivity analysis
Week 6 and week 12 results in the topline announcement, March 2025
Week 12 placebo-adjusted result in the annual report
Responder analysis: office systolic blood pressure below 130 mm Hg and reductions of 5, 10, and 20 mm Hg at week 12
Participants with and without chronic kidney disease: systolic blood pressure and albuminuria at week 12
Participants with and without chronic kidney disease: results by stage
| CKD stage (placebo N; lorundrostat 50 mg N) | Placebo AOSBP LSM (95% CI) change at week 12 | Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12 | Placebo adjusted (95% CI) | Placebo week 12 % with AOSBP <130 mmHg | Lorundrostat 50 mg week 12 % with AOSBP <130 mmHg |
|---|---|---|---|---|---|
| No CKD (202; 406) | “-7.2 (-11.3, -3.2)” | “-19.4 (-22.2, -16.6)” | “-12.2 (-17.1, -7.3)” | “22.1” | “48.0” |
| Stage 1 (30; 58) | “-8.9 (-15.4, -2.3)” | “-19.5 (-24.1, -14.9)” | “-10.6 (-18.6, -2.6)” | “18.4” | “50.6” |
| Stage 2 (25; 31) | “-9.1 (-15.9, -2.4)” | “-16.7 (-22.6, -10.8)” | “-7.6 (-16.5, 1.4)” | “12.0” | “28.4” |
| Stage 3 (10; 38) | “-8.5 (-18.1, 1.1)” | “-18.5 (-24.1, -13.0)” | “-10.1 (-21.1, 1.0)” | “30.0” | “47.0” |
Participants with chronic kidney disease: P values and albuminuria population
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events by randomized group
Overall adverse events, serious adverse events, and deaths
“Treatment-emergent adverse events were experienced by 49.9% of participants (538/1078) and were mostly mild or moderate in severity (Table 3). Serious adverse events occurred in 22 participants and included 1 event that was considered to be related to treatment. One participant in the placebo group died after week 6 (unrelated to treatment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definitions used in the adverse event table
“Defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Confirmed by adrenocorticotropic hormone (cosyntropin or regional equivalent) stimulation test; trial drug was discontinued.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum potassium above 6.0 mmol/L
“A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo (eTable 4 in Supplement 1). The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range (eFigure 5 in Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum sodium and potassium thresholds by randomized group
| Level, n (%) | Lorundrostat 50 to 100 mg daily (n=270) | Lorundrostat 50 mg (n=538) | Placebo (n=270) |
|---|---|---|---|
| Serum sodium <132 mmol/L | “22 (8.1)” | “38 (7.1)” | “13 (4.8)” |
| Serum sodium <130 mmol/L | “11 (4.1)” | “14 (2.6)” | “4 (1.5)” |
| Serum sodium <125 mmol/L | “4 (1.5)” | “4 (0.7)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, single value | “29 (10.7)” | “38 (7.1)” | “3 (1.1)” |
| Serum potassium 6.1 to 6.5 mmol/L, single value | “2 (0.7)” | “5 (0.9)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, single value | “2 (0.7)” | “1 (0.2)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, confirmed | “24 (8.9)” | “31 (5.8)” | “2 (0.7)” |
| Serum potassium 6.1 to 6.5 mmol/L, confirmed | “2 (0.7)” | “3 (0.6)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, confirmed | “1 (0.4)” | “0” | “0” |
Counting rules for the sodium and potassium table
Confirmed hyperkalemia reported by the company
Kidney function: creatinine-based and cystatin C-based eGFR
“Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cortisol and glucocorticoid insufficiency
“At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group. No participants treated with lorundrostat experienced a glucocorticoid deficiency (confirmed by stimulation testing; Table 3). There were no reports of hyperadrenocorticism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment discontinuation due to hyperkalemia, hyponatremia, or reduced kidney function
“Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR). Among participants in the placebo group, there were no treatment discontinuations due to hyperkalemia, hyponatremia, or reduction in kidney function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events reported in the topline announcement
Confirmed hyperkalemia and symptomatic hypotension in the responder analysis
Participants with chronic kidney disease: potassium and cystatin C-based eGFR
Study limitations
Summary: study limitations
Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.
In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.
Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.
Limitations stated by the investigators
“This trial has limitations. First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice. Importantly, the phase 2 Advance-HTN trial18 of lorundrostat used 24-hour ambulatory BP measurements and, compared with placebo, demonstrated similar patterns of BP lowering after 12 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the current trial compared the efficacy of lorundrostat vs placebo, but the trial did not include an active comparator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote